Exercise During Active Surveillance for Prostate Cancer (ERASE)
8. April 2022 aktualisiert von: University of Alberta
A Phase II Randomized Controlled Trial of Exercise in Prostate Cancer Patients Undergoing Active Surveillance
The broad goal of the Exercise During Active Surveillance for Prostate Cancer (ERASE) trial is to examine the effects of exercise in prostate cancer patients undergoing active surveillance.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The ERASE Trial will be a phase II randomized controlled trial.
A total of 66 men with low- or intermediate-grade clinically localized prostate cancer undergoing active surveillance will be randomized to either a 12-week of supervised high-intensity aerobic interval training or usual care.
The primary outcome will be peak oxygen consumption (VO2peak) as a measure of physical fitness.
The secondary outcomes include tumour-related biomarkers, fear of cancer progression, quality of life, and psychological distress.
Exploratory outcomes will include indicators of cancer progression including prostate-specific antigen.
Based on this sample size, our study has 80% power with a two-tailed alpha <0.05 to detect a clinically meaningful effect of 3.5 ml/kg/min on our primary outcome of VO2max.
This power will also be sufficient for detecting differences in our secondary biomarkers and patient-reported outcomes if the effects are at least moderate (i.e., a standardized effect size of d=0.60).
Studientyp
Interventionell
Einschreibung (Tatsächlich)
52
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G2H9
- University of Alberta
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Männlich
Beschreibung
Inclusion Criteria:
- ≥18 years of age
- diagnosed with low or favorable intermediate grade localized PCa defined as PSA less than 10, Gleason Score 3+3 or 3+4 with low volume, and digital rectal examination (DRE) of T1C or T2A
- initiating or continuing active surveillance with no plans for treatment for prostate cancer in the next 6 months (e.g., radical prostatectomy, radiotherapy, or androgen deprivation therapy)
- screened for medical clearance for exercise testing and participation in vigorous aerobic exercise
- residing in a commutable area near Edmonton, Alberta
- willing to commute to the Behavioural Medicine Fitness Centre three times per week to attend a 12-week supervised high-intensity aerobic interval exercise program
Exclusion Criteria:
- having comorbidities or uncontrolled medical conditions that their referred clinicians indicate as inappropriate to participate in exercise (e.g., known cardiac disease or uncontrolled hypertension)
- having contraindications for cardiopulmonary stress and/or physical fitness tests
- currently participating in a structured, vigorous exercise program.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Exercise Group
Supervised high-intensity aerobic interval training (HIIT) during active surveillance
|
A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
|
|
Kein Eingriff: Usual Care Group
The usual care group will be provided with standard active surveillance medical care.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Changes of Peak Oxygen Consumption (VO2peak)
Zeitfenster: At baseline and 12-week (postintervention)
|
VO2peak is a measure of cardiopulmonary fitness and a powerful surrogate outcome for cancer-specific and overall survival.
VO2peak will be defined as the highest oxygen-uptake value recorded during the test and quantified where participants reach a plateau in oxygen consumption, which will be expressed as relative to body mass (i.e., ml O2·kg-1·min-1).
|
At baseline and 12-week (postintervention)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Changes of Natural Killer Cell Cytotoxic Activity (NKCA) and Counts
Zeitfenster: At baseline and 12-week (postintervention)
|
NKCA significantly contributes to the regulation of tumour suppression in response to exercise and it has been demonstrated to have a diagnostic value in patients with cancer.
NK cell activities are assessed using blood analysis as the total number of circulating NK cells and their cytotoxic activity.
NK cell counts and NKCA will be measured using the phenotypic markers of NK cells (CD3-CD16+CD56+).
NKCA will be expressed as the percentage of target cells killed by a sample of 100,000 peripheral blood mononuclear cells at the effector-to-target ratios of 5:1, 20:1, 40:1, and 100:1.
|
At baseline and 12-week (postintervention)
|
|
Changes of Immune-Related Phenotype
Zeitfenster: At baseline and 12-week (postintervention)
|
Immune-related phenotypic markers, including CD3, CD16, CD56, and CD107 (on the frozen) and CD4, CD8, CD20, CD25, CD11, CD45RA, CD45RO, CD16, CD56, CD107 activation (fresh on whole blood), will be assessed using blood samples.
|
At baseline and 12-week (postintervention)
|
|
Changes of Prostate-Specific Antigen (PSA)
Zeitfenster: At baseline, 12-week (postintervention)
|
PSA will be assessed using blood samples.
|
At baseline, 12-week (postintervention)
|
|
Changes of Complete Blood Count with Differential (CBCD)
Zeitfenster: At baseline and 12-week (postintervention)
|
CBCD, including RBC, WBC, HGB, HCT, PLT, LYMPH, BASO, EOS, MONO, NEUT, will be assessed using blood samples.
|
At baseline and 12-week (postintervention)
|
|
Changes of Insulin
Zeitfenster: At baseline and 12-week (postintervention)
|
Fasting insulin levels will be assessed using blood samples.
|
At baseline and 12-week (postintervention)
|
|
Changes of Fasting Glucose
Zeitfenster: At Baseline and 12-week postintervention
|
Fasting glucose levels will be assessed using blood samples.
|
At Baseline and 12-week postintervention
|
|
Changes of HbA1c
Zeitfenster: At Baseline and 12-week postintervention
|
HbA1c will be assessed using using blood samples.
|
At Baseline and 12-week postintervention
|
|
Changes of Insulin-like Growth Factor (IGF)-axis
Zeitfenster: At baseline and 12-week (postintervention)
|
IGF-axis, including circulating IGF-1 and IGF binding protein(IGFBP)-3, will be assessed using blood samples.
|
At baseline and 12-week (postintervention)
|
|
Changes of Pro-Inflammatory Cytokines
Zeitfenster: At baseline and 12-week (postintervention)
|
Pro-inflammatory cytokines, including IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-α, will be assessed.
|
At baseline and 12-week (postintervention)
|
|
Changes of High-Sensitivity C-Reactive Protein (hs-CRP)
Zeitfenster: At Baseline and 12-week postintervention
|
hs-CRP will be assessed using blood samples.
|
At Baseline and 12-week postintervention
|
|
Changes of Adiponectin
Zeitfenster: At Baseline and 12-week postintervention
|
Adiponectin will be assessed using blood samples.
|
At Baseline and 12-week postintervention
|
|
Physical Function
Zeitfenster: At Baseline and 12-week postintervention
|
Physical function, consisting of strength, flexibility, and agility components, will be assessed by the Senior's Fitness Test (SFT).
|
At Baseline and 12-week postintervention
|
|
Health-Related Quality of Life
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Health-related quality of life will be assessed using the European Organization for Research and Treatment of Cancer- Quality of Life Questionnaire (EORTC-QLQ) - C30 questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Prostate Cancer-Specific Quality of Life
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Prostate cancer-specific quality of life will be assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Fear of Cancer Progression
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Fear of cancer progression will be assessed using the Fear of Cancer Recurrence Inventory (FCRI) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Cancer Worry
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Cancer worry will be assessed using the Cancer Worry Scale (CWS) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
General Anxiety
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
General anxiety will be assessed using the Anxiety (general): Spielberger State-Trait Anxiety Inventory (STAI) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Prostate Cancer-Specific Anxiety
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Prostate cancer-specific anxiety will be assessed using the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Depression
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Depression will be assessed using the Epidemiologic Studies Depression Scale (CES-D) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Perceived Stress
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Perceived stress will be assessed using the Perceived Stress Scale (PSS) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Self-esteem
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Self-esteem will be assessed using the Rosenberg Self-Esteem Scale (RSES) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Fatigue
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Fatigue will be assessed using the Functional Assessment of Cancer Therapy- Fatigue (FACT-F) questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Physical Activity Level
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Physical activity level, consisting of light-, moderate-, and vigorous aerobic exercise and resistance exercise, will be assessed using the Godin Leisure-Time Exercise Questionnaire (GLTEQ).
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Exercise Motivation
Zeitfenster: At baseline, 12-week (postintervention), 6-month, and 12-month
|
Exercise motivation, consisting of Theory of Planned Behaviour (TPB) constructs (instrumental and affective attitudes, subjective norms, intention and perceived behavioral control), will be assessed using questionnaire.
|
At baseline, 12-week (postintervention), 6-month, and 12-month
|
|
Body composition
Zeitfenster: At baseline and 12-week (postintervention)
|
Body composition, including body weight and waist- and hip-circumferences, will be assessed using weight scales and a tape measure.
|
At baseline and 12-week (postintervention)
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Kerry S Courneya, PhD, University of Alberta
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Kang DW, Fairey AS, Boule NG, Field CJ, Wharton SA, Courneya KS. Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance: The ERASE Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1487-1495. doi: 10.1001/jamaoncol.2021.3067.
- Kang DW, Fairey AS, Boule NG, Field CJ, Wharton SA, Courneya KS. A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance. J Urol. 2022 Apr;207(4):814-822. doi: 10.1097/JU.0000000000002334. Epub 2022 Feb 17.
- Kang DW, Boule NG, Field CJ, Fairey AS, Courneya KS. Effects of supervised high-intensity interval training on motivational outcomes in men with prostate cancer undergoing active surveillance: results from a randomized controlled trial. Int J Behav Nutr Phys Act. 2022 Sep 29;19(1):126. doi: 10.1186/s12966-022-01365-2.
- Kang DW, Fairey AS, Boule NG, Field CJ, Courneya KS. Exercise duRing Active Surveillance for prostatE cancer-the ERASE trial: a study protocol of a phase II randomised controlled trial. BMJ Open. 2019 Jul 4;9(7):e026438. doi: 10.1136/bmjopen-2018-026438.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
1. Juli 2018
Primärer Abschluss (Tatsächlich)
31. Mai 2020
Studienabschluss (Tatsächlich)
31. Mai 2021
Studienanmeldedaten
Zuerst eingereicht
20. Juni 2017
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
28. Juni 2017
Zuerst gepostet (Tatsächlich)
29. Juni 2017
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
18. April 2022
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
8. April 2022
Zuletzt verifiziert
1. November 2021
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HREBA.CC-17-0248
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur High-intensity aerobic interval training (HIIT)
-
Duke UniversityVanderbilt UniversityAbgeschlossenHochintensives Intervalltraining | Kritische Krankheit | Covid19 | Fitness-Tracker | Intensivstation | IntensivstationenVereinigte Staaten
-
University of Illinois at Urbana-ChampaignNational Institute on Aging (NIA); Northeastern UniversityNoch keine Rekrutierung
-
University of CadizMinisterio de Ciencia e Innovación, SpainRekrutierungHerz-Kreislauf-Erkrankungen | Diabetes mellitus, Typ 2 | Fettverbrennung | StoffwechselstörungSpanien
-
University of CadizMinisterio de Ciencia e Innovación, SpainRekrutierungDiabetes mellitus, Typ 2Spanien